Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $1,762,950.00 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 35,000 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the transaction, the chief executive officer directly owned 958,100 shares in the company, valued at $48,259,497. The trade was a 3.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Supernus Pharmaceuticals Trading Down 3.0%

Shares of NASDAQ SUPN opened at $49.29 on Thursday. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $59.68. The business has a 50-day moving average price of $51.22 and a two-hundred day moving average price of $49.17. The firm has a market capitalization of $2.84 billion, a PE ratio of -72.48, a PEG ratio of 1.58 and a beta of 0.70.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SUPN. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Finally, Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $62.17.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. grew its stake in Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares during the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $49,000. USA Financial Formulas bought a new stake in Supernus Pharmaceuticals during the third quarter valued at about $50,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $51,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.